Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000270917 is classified as a pseudogene for Chromatin Assembly Factor 1, Subunit A (CHAF1A, p150)[4]. Pseudogenes typically arise from duplication or retrotransposition events and generally do not produce functional proteins; they lack intact coding sequences or have disruptive mutations[2][6]. Unlike true protein-coding genes, pseudogenes are not considered therapeutic targets, do not encode receptors, enzymes, or other actionable proteins, and do not have associated drug interactions, mechanisms of action, biomarker utility, or therapeutic safety concerns. Furthermore, while the canonical CHAF1A is broadly involved in chromatin assembly and maintenance with links to several biological pathways and diseases[5], the pseudogene does not share these functional properties and is primarily an inactive genomic locus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on chromatin assembly factor 1, subunit A pseudogene.